Publications by authors named "Thomas Radimerski"

38Publications

A proteomic study of myeloproliferative neoplasms using reverse-phase protein arrays.

Leuk Lymphoma 2020 Dec 15;61(13):3052-3065. Epub 2020 Aug 15.

Departmento de Análises Clínicas Toxicológicas e Bromatológicas da Faculdade de Ciências Farmacêuticas de Ribeirão Preto, Universidade de São Paulo, Brazil.

View Article and Find Full Text PDF
December 2020

Discovery and Structural Characterization of ATP-Site Ligands for the Wild-Type and V617F Mutant JAK2 Pseudokinase Domain.

ACS Chem Biol 2019 04 11;14(4):587-593. Epub 2019 Mar 11.

Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School and Department of Cancer Biology , Dana-Farber Cancer Institute , Boston , Massachusetts 02115 , United States.

View Article and Find Full Text PDF
April 2019

Effects of Jak2 type 1 inhibitors NVP-BSK805 and NVP-BVB808 on Jak2 mutation-positive and Bcr-Abl-positive cell lines.

Acta Haematol 2014 31;132(1):75-86. Epub 2014 Jan 31.

Medizinische Klinik m.S. Hämatologie und Onkologie, Campus Virchow Klinikum, Charité, Universitätsmedizin Berlin, Berlin, Germany.

View Article and Find Full Text PDF
September 2014

Targeting PI3K, HER2 and the IL-8/JAK2 axis in metastatic breast cancer: Which combination makes the whole greater than the sum of its parts?

Drug Resist Updat 2013 Jul-Nov;16(3-5):68-72. Epub 2013 Oct 10.

Friedrich Miescher Institute for Biomedical Research, Basel, Switzerland.

View Article and Find Full Text PDF
June 2014

JAK1/2 and Pan-deacetylase inhibitor combination therapy yields improved efficacy in preclinical mouse models of JAK2V617F-driven disease.

Clin Cancer Res 2013 Nov 30;19(22):6230-41. Epub 2013 Sep 30.

Authors' Affiliations: Disease Area Oncology and Preclinical Safety, Discovery and Investigative Pathology, Novartis Institutes for BioMedical Research, Basel, Switzerland.

View Article and Find Full Text PDF
November 2013